SCHEMBL5652276

SCHEMBL5652276

CC1CN(C(=O)c2ccccc2)CCN1S(=O)(=O)c1ccc(C(=O)c2cccs2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MMP1 P03956 3/20 0.50
MMP3 P08254 3/20 0.50
MMP7 P09237 3/20 0.50
MMP9 P14780 3/20 0.50
MMP13 P45452 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA9 Q16790 3/20 0.50
CA12 O43570 1/20 0.50
CA7 P43166 1/20 0.50
CA4 P22748 2/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14367034 1.00 LMNA (0.52) LMNAALOX15TSHRHSD17B10MMP1
SCHEMBL5654242 0.88 MMP1 (0.56) LMNATSHRMMP1MMP3MMP7
SCHEMBL5651311 0.85 MMP1 (0.48) MMP1MMP3MMP7MMP9MMP13
SCHEMBL14367061 0.84 LMNA (0.50) LMNAALOX15TSHRHSD17B10MMP1
SCHEMBL5322126 0.82 GCKR (0.51) LMNAALOX15TSHRHSD17B10MMP1
SCHEMBL5324458 0.81 MMP1 (0.55) LMNATSHRMMP1MMP3MMP7
SCHEMBL3715208 0.81 MMP1 (0.55) LMNATSHRMMP1MMP3MMP7
SCHEMBL5324461 0.81 MMP1 (0.55) LMNATSHRMMP1MMP3MMP7
SCHEMBL5324061 0.81 MMP1 (0.58) MMP1MMP3MMP7MMP9MMP13
SCHEMBL7892693 0.81 MMP1 (0.55) LMNATSHRMMP1MMP3MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259879-A1 Piperazine and piperidine biaryl derivatives CYP3A5, CYP3A43, CCR5 LMNA 2555/4885ALOX15 2741/4885TSHR 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.